Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2015

View Archived Issues

Chong Kun Dang Holdings reports HDAC6 inhibitors

Beaufour Ipsen Tianjin Pharmaceutical reports androgen receptor degradation enhancers

Telotristat etiprate achieves primary endpoint in phase III trial in carcinoid syndrome

Bayer starts pilot study of BAY-1142524 in left ventricular dysfunction after MI

rVZV-ZEBOV Ebola vaccine up to 100% effective, interim results of West African trial indicate

Cancer antigen-125 levels, a potential biomarker of long-term mortality in COPD

ContraVir Pharmaceuticals enrolls first patient in pivotal phase III trial of FV-100

Bristol-Myers Squibb patents lipase inhibitors

Amgen highlights milestones from second quarter 2015

Merck & Co. discloses ROMK channel blockers

Analytical Services develops polyphenol conjugates for cancer

ADMA Biologics files BLA for immune globulin RI-002

Cidara Therapeutics begins phase I study of CD-101 IV

Clovis Oncology completes regulatory submissions for Rociletinib

Omidria approved in the E.U.

Dermira begins phase III program in axillary hyperhidrosis for DRM-04

biOasis's MTfp-I2S effective in mouse model of Hunter syndrome

BMS joins immuno-oncology initiative for high-risk cancers

Shire acquires Foresight Biotherapeutics and gains phase II conjunctivitis drug

Formula Pharmaceuticals licenses rights to transposon-based gene transfer technology

Charleston Laboratories begins enrollment in a phase I study of CL-H1T

Amarantus partners with U.S. Army and Rutgers University to develop skin replacement

Protalix's oral anti-TNF fusion protein safe and well tolerated in phase I trial

Abbott makes deals with heart valve device developers Tendyne and Cephea

Io Therapeutics partners with the National Multiple Sclerosis Society

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...